ExPLoRNA Therapeutics presents a family of compounds inspired by biology. Our vast library of cap analogs offers unprecedented opportunity to create tailor made mRNA for vaccines and therapeutics products.
mRNA has also emerged as both a disruptive and highly promising technology providing access to new class of medicines
mRNA consist of the coding region, which contains all the information about protein sequence, and several regulatory elements that stabilize mRNA and guide protein production machinery to mRNA.
These elements include mRNA cap at the 5′ end and polyA tail at the 3′ end of mRNA.
mRNA technology has emerged as both a disruptive and highly promising new class of medicines.
The new mRNA technology innovations, combined with the unique know-how of ExploRNA’s scientific team, provide a unique opportunity to harness this cutting-edge technology to revolutionize therapy and prevention of many diseases.
ExploRNA’s two lead development programs are focusing on tumor specific antigen vaccines and the expression of cytokines to promote cytotoxic T cells to eliminate tumor growth.
mRNA has the potential to treat any disease where expression of protein(s) will drive the alleviation of the symptoms or causes of the disease.
A strong intellectual property position based on science excellence
ExploRNA Therapeutics Sp. z o. o.
Żwirki i Wigury 93 lok. 2157
02-089 Warsaw, Poland
info@explorna.com
Copyright © 2024 ExploRNA Therapeutics
All rights reserved
